USPTO Extends "Patents 4 Patients" Pilot Program

Last summer, we wrote about the “Patents 4 Patients” Cancer Immunotherapy Pilot Program launched by the USPTO. At the program’s launch, the scheduled expiration date was June 29, 2017. However, earlier today, the USPTO announced that the program has been extended until December 31, 2018. The USPTO’s announcement only concerns the expiration date; no substantive changes to the program’s requirements were announced.

In view of today’s announcement, applicants wishing to file a petition for special consideration under the Cancer Immunotherapy Pilot Program must do so on or before December 31, 2018. 
For more information about the program’s requirements, view our earlier post here.


We use cookies to give you the best online experience. By agreeing you accept the use of cookies in accordance with our cookie policy.